S

SELLAS Life Sciences Group
D

SLS

0.98500
USD
-0.16
(-13.60%)
مغلق
حجم التداول
346,494
الربح لكل سهم
-0
العائد الربحي
-
P/E
-1
حجم السوق
69,326,249
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ALT
    0.12500
    (1.80%)
    7.06500 USD
    A
    ARWR
    1.830
    (9.28%)
    21.540 USD
    I
    IMRN
    0.03000
    (1.39%)
    2.19000 USD
    P
    PAVM
    -0.06000
    (-9.23%)
    0.59000 USD
    T
    TNXP
    0.01300
    (4.10%)
    0.33000 USD
    المزيد
الأخبار
المقالات

العنوان: SELLAS Life Sciences Group

القطاع: Healthcare
الصناعة: Biotechnology
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.